Orbicular Wins Health Canada Nod for g-Ozempic with Apotex

OneSource supports second generic semaglutide approval in Canada

OneSource Specialty Pharma, a leading specialty pharmaceutical CDMO, announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in one of the world’s most significant semaglutide markets. The milestone ref…

Orbicular Wins Health Canada Nod for g-Ozempic with Apotex

Generic Semaglutide Injection developed by Orbicular receives Notice of Compliance from Health Canada — our second G-7 Approval by stringent regulatory authority (SRA) to greenlight the program after the U.S. FDA’s Tentative Approval A fully indigenous Indian innovation: API, pen device, formulation, manufacturing and analytical technology developed end-to-end within India Orbicular Pharmaceutical Technologies Pvt. Ltd., a specialty pharmaceutic…